Sima Canaan–Kühl

After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy

Thomas Rauen, Stephanie Wied, Christina Fitzner et al. · Kidney International · 2020 · 193 citations

Family Medicine, Glomerulonephritis, Urology +8

Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease

Malte Lenders, Leon Paul Neußer, Michael Rudnicki et al. · Journal of the American Society of Nephrology · 2018 · 72 citations

Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction Versus Treatment Switch

Frank Weidemann, Johannes Krämer, Thomas Duning et al. · Journal of the American Society of Nephrology · 2014 · 68 citations · Full text

Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS)

Malte Lenders, Peter Nordbeck, Christine Kurschat et al. · Clinical Pharmacology & Therapeutics · 2020 · 65 citations

Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant

Malte Lenders, Frank Weidemann, Christine Kurschat et al. · Orphanet Journal of Rare Diseases · 2016 · 64 citations · Full text